- Home
- BLTE vs NEO Comparison
BLTE vs NEO Comparison
Compare BLTE & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLTE
- NEO
- Stock Information
- Founded
- BLTE 2018
- NEO 2001
- Country
- BLTE United States
- NEO United States
- Employees
- BLTE N/A
- NEO N/A
- Industry
- BLTE Biotechnology: Pharmaceutical Preparations
- NEO Precision Instruments
- Sector
- BLTE Health Care
- NEO Health Care
- Exchange
- BLTE Nasdaq
- NEO Nasdaq
- Market Cap
- BLTE 2.1B
- NEO 1.9B
- IPO Year
- BLTE 2022
- NEO 1999
- Fundamental
- Price
- BLTE $82.46
- NEO $15.39
- Analyst Decision
- BLTE Strong Buy
- NEO Strong Buy
- Analyst Count
- BLTE 4
- NEO 8
- Target Price
- BLTE $89.00
- NEO $20.25
- AVG Volume (30 Days)
- BLTE 107.6K
- NEO 722.4K
- Earning Date
- BLTE 11-12-2024
- NEO 11-05-2024
- Dividend Yield
- BLTE N/A
- NEO N/A
- EPS Growth
- BLTE N/A
- NEO N/A
- EPS
- BLTE N/A
- NEO N/A
- Revenue
- BLTE N/A
- NEO $644,118,000.00
- Revenue This Year
- BLTE N/A
- NEO $12.93
- Revenue Next Year
- BLTE N/A
- NEO $9.70
- P/E Ratio
- BLTE N/A
- NEO N/A
- Revenue Growth
- BLTE N/A
- NEO 12.06
- 52 Week Low
- BLTE $31.01
- NEO $12.77
- 52 Week High
- BLTE $86.53
- NEO $21.22
- Technical
- Relative Strength Index (RSI)
- BLTE 72.06
- NEO 56.48
- Support Level
- BLTE $80.00
- NEO $14.81
- Resistance Level
- BLTE $84.50
- NEO $16.60
- Average True Range (ATR)
- BLTE 4.46
- NEO 0.67
- MACD
- BLTE -0.22
- NEO 0.01
- Stochastic Oscillator
- BLTE 83.18
- NEO 62.77
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About NEO NeoGenomics Inc.
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.